Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.70 Bn | 194.10 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 127.86 Bn | 124.38 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 119.05 Bn | 109.83 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.61 Bn | 73.07 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 52.00 Bn | 47.75 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.36 Bn | 32.42 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.85 Bn | 31.74 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.38 Bn | 23.06 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.08 Bn | 22.59 Bn | 684.20 Mn | 17.54% |
| 10 | Nu-Med Plus | 2.03 Mn | 2.02 Mn | - | 41.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -31.93% |
| Sep 30, 2025 | 40.93% |
| Jun 30, 2025 | 41.43% |
| Mar 31, 2025 | 30.61% |
| Dec 31, 2024 | 83.10% |
| Sep 30, 2024 | 45.96% |
| Jun 30, 2024 | 58.54% |
| Mar 31, 2024 | 60.60% |
| Dec 31, 2023 | 51.87% |
| Sep 30, 2023 | 66.93% |
| Jun 30, 2023 | 70.09% |
| Mar 31, 2023 | 43.13% |
| Dec 31, 2022 | 30.06% |
| Sep 30, 2022 | 27.22% |
| Jun 30, 2022 | 38.38% |
| Mar 31, 2022 | 48.16% |
| Dec 31, 2021 | -83.49% |
| Sep 30, 2021 | 38.84% |
| Jun 30, 2021 | -13.97% |
| Mar 31, 2021 | -37.39% |